Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution

Fig. 2

Modeled course of MMP-1, MMP-3, SAA, and CRP levels in the first 24 months after DMARD initiation, in ACPA-negative RA patients achieving SDFR and those who did not achieve SDFR.

Biomarker levels were measured at baseline, 12 months, and 24-months and modeled to visualize the differences between the SDFR and non-SDFR groups between baseline and 12 months and between 12 and 24 months. Before modeling, biomarker levels were log-transformed. In the SDFR group, MMP-1, MMP-3, SAA, and CRP showed a statistically significant stronger decline in the first 12 months after DMARD start compared to the non-SDFR group. Vertical dotted lines indicate the transition from one time period (0–12 months) to the following (12–24 months) which were separately estimated. CRP, C-reactive protein; MMP, matrix metalloproteinase; SAA, serum A amyloid; SDFR, sustained DMARD-free remission

Back to article page